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Abstract
Growth hormone (GH) is used to treat short stature and growth failure associated with 
growth disorders. Birth size and GH status variably modulate response to GH therapy. 
The aim of this study was to determine the effect of birth size on response to GH 
therapy, and to determine the impact of GH status in patients born small for gestational 
age (SGA) on response to GH therapy. Data from the prospective, non-interventional 
American Norditropin Studies: Web-Enabled Research (ANSWER) Program was analyzed 
for several growth outcomes in response to GH therapy over 3 years. GH-naïve children 
from the ANSWER Program were included in this analysis: SGA with peak GH ≥10 ng/mL 
(20 mIU/L), SGA with peak GH <10 ng/mL (20 mIU/L), isolated growth hormone deficiency 
(IGHD) born SGA, IGHD not born SGA and idiopathic short stature. For patients with 
IGHD, those who did not meet criteria for SGA at birth showed greater improvements 
in height SDS and BMI SDS than patients with IGHD who met criteria for SGA at birth. 
For patients born SGA, response to GH therapy varied with GH status. Therefore, unlike 
previous guidelines, we recommend that GH status be established in patients born SGA 
to optimize GH therapy.
Introduction
Treatment with recombinant human growth hormone 
(GH) is widely utilized for improving height in 
children with growth failure and conditions in which 
it is efficacious, including isolated growth hormone 
deficiency (IGHD), idiopathic short stature (ISS) and 
small for gestational age (SGA) (1, 2). Although clinical 
characteristics of these growth disorders often overlap, 
criteria for SGA can be distinguished from those of other 
GH disorders in that diagnosis is defined by having a birth 
weight and/or length of <−2.0 standard deviation scores 
(SDS) for gestational age (3). Retrospective studies indicate 
that approximately one-quarter of children with short 
stature (4) and one-third of children with IGHD (5) were 
reported to have historical auxological data consistent 
with being born SGA.
The effectiveness of GH therapy for increasing short-
term growth rates and adult height in patients with 
various growth disorders is well documented (6, 7, 8, 9, 
10, 11). For example, 2  years of GH treatment resulted 
in an increase from baseline in height SDS (HSDS) in 
children with Noonan syndrome, Turner syndrome, ISS, 
SGA, IGHD and multiple pituitary hormone deficiency 
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(MPHD) (12, 13). Additional studies have also shown 
improved growth outcomes in these disorders after 4 
to 5 years of GH treatment (7, 9, 14, 15) and improved 
growth outcomes associated with starting GH therapy 
at an earlier age in prepubertal children and for a longer 
duration (9, 12, 13, 15). Despite these demonstrated 
benefits of GH replacement therapy (6, 8, 10, 11), 
response to treatment with GH is substantially variable 
among diagnostic categories and among individuals 
with the same disorder (16, 17). For example, greater 
linear growth in response to 2 years of GH therapy was 
seen in children with SGA compared with those with 
IGHD (6). Several factors, including genetics, diagnosis 
and biochemical variability, contribute to differences 
in responsiveness to GH therapy (18) and complicate 
treatment decisions regarding GH therapy, such as when 
to start treatment and what dosage is appropriate. In an 
attempt to explain variability in response to GH therapy, 
several mathematical models have been developed as 
practical tools to estimate the response to GH therapy for 
the diagnosis of growth hormone deficiency (GHD) (19), 
SGA (20) and ISS (21).
The non-interventional American Norditropin 
Studies: Web-Enabled Research (ANSWER) Program was 
launched in 2002 and designed to assess the real-life 
clinical outcomes of pediatric and adult patients treated 
with Norditropin as prescribed by physicians according 
to standard clinical practice (22). Prospective collection 
of data through the US-based ANSWER Program offered 
the possibility to gather new insights into GH treatment 
effects in specific diagnostic populations, with respect 
to patient characteristics, diagnosis, age, sex and 
pubertal status. Previous publications from the ANSWER 
Program have shown that treatment with GH was 
efficacious in increasing HSDS from baseline in children 
with IGHD, MPHD, ISS, Noonan syndrome and Turner 
syndrome (7, 13). Additionally, some reports have 
investigated the effects of baseline characteristics (eg, 
HSDS, age, insulin-like growth factor 1 (IGF-I) SDS) on 
changes in HSDS in response to GH therapy over time 
(12, 13). The analysis described here evaluated growth 
outcomes (HSDS, IGF-I SDS and BMI SDS), bone age per 
chronological age (BA/CA) and GH dose over 3 years of 
treatment in the IGHD, ISS and SGA (GH-sufficient or 
-deficient) pediatric populations. The objective of this 
report is to assess whether GH responses in patients 
born SGA are affected by GH sufficiency/deficiency as 
indicated by GH stimulation tests and to evaluate the 
effect of birth size on response to GH therapy in patients 
with IGHD.
Patients and methods
Study design
Data were extracted from the prospective, non-
interventional ANSWER Program, which was launched 
in 2002 and aimed to evaluate long-term safety and 
effectiveness outcomes of US pediatric and adult patients 
treated with Norditropin (somatropin (rDNA origin) 
injection; Novo Nordisk A/S) (23). The ANSWER Program 
enrolled adults and children prescribed Norditropin for 
treatment of GHD or other growth disorders. Informed 
consent from patients or their parents or guardians and 
approval by the appropriate institutional review board 
were obtained prior to study enrollment. Participating 
physicians recorded patient histories and physical 
examination data using the NovoNet Web-based research 
platform. Data collected at initial patient visits included 
baseline HSDS, weight, bone age, maximal stimulated 
serum GH concentration and serum IGF-I levels. Patient 
information collected at follow-up visits included GH 
dose/frequency, height, weight, IGF-I concentration and 
bone age. GH doses were determined by the treating 
physicians (22). Study protocols and documentation 
were approved by institutional review boards at each 
clinical site, and patients were required to provide 
informed consent before the start of any study-related 
activities. This study was conducted in accordance 
with the Declaration of Helsinki, and all data are 
anonymized. The ANSWER Program is guided by Good 
Pharmacoepidemiology Practice guidelines for design 
and reporting of epidemiologic studies, as defined by 
the International Society for Pharmacoepidemiology and 
Strengthening the Reporting of Observational studies in 
Epidemiology guidelines (22).
Analysis population
The analyses of data from the ANSWER Program described 
in this report evaluated changes in growth-related 
clinical end points in response to 3  years of treatment 
with Norditropin. The analysis population included GH 
treatment-naïve children (aged <18  years at the end of 
3 years of data collection) diagnosed with ISS, IGHD or SGA 
(defined as having a birth weight and/or body length SDS 
of <−2.0 for gestational age). ISS was defined as idiopathic 
short stature when excluding all other potential causes of 
growth failure. Diagnostic classification was determined 
by the participating physician who evaluated the patient. 
The IGHD population was subdivided based on fulfillment 
of SGA criteria according to historical auxological 
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data, and the SGA population was subdivided by peak GH 
levels at baseline (<10 vs ≥10 ng/mL, or <20 vs ≥20 mIU/L) 
as determined by GH stimulation test. This cutoff point of 
10 ng/mL (20 mIU/L) is commonly considered a threshold 
indicating normal or below normal GH levels (1); 
therefore, for the SGA population, a level of ≥10 ng/mL 
(20 mIU/L) was considered indicative of GH sufficiency, 
while a peak GH level of <10 ng/mL (20 mIU/L) was 
considered to indicate GH deficiency. In the ISS cohort, no 
patients had historical auxological data that fulfilled SGA 
criteria. Subpopulations are mutually exclusive; patients 
with IGHD born SGA were not included in SGA groups.
Only patients who were Tanner stage 1 (prepubertal) at 
baseline were included. Patients with prior GH treatment 
who started more than 1  week prior to enrollment were 
excluded. We also excluded patients with missing birth 
weight and/or length information at baseline (enrollment 
visit). Participants with missing, inconsistent or improbable 
baseline values of key variables (height, BMI, BA, CA, gender 
and IGF-I) or any of the GH response end points above were 
also excluded. Since many patients were missing baseline 
GH peak values and/or IGF-I values and/or BA imaging 
values at baseline, we used in lieu of missing any of these 
three baseline values the values from the closest visit date 
to enrollment date within the interval from 18  months 
before to 12 months after the enrollment date.
Variables and statistical analysis
Clinical end points included HSDS, BMI SDS, bone age 
per chronological age (BA/CA), insulin-like growth 
factor 1 (IGF-I) SDS and GH dose. HSDS and BMI SDS 
(z-scores) were calculated from actual height and weight 
using standard references provided by the US Centers for 
Disease Control and Prevention (24). IGF-I values were 
measured locally and transformed into IGF-I SDS based 
on age- and sex-related normative values of Brabant 
et al. (25). Reported means, including those referring to 
change over baseline values, were calculated as a mean 
of the patients within each subpopulation. Patients with 
missing birth weight and/or length information or with 
missing baseline values of key variables (height, BMI, BA, 
CA, gender and IGF-I) or any of the clinical end points 
were excluded. Only observed values were used in the 
analysis; missing values were not imputed. Participants 
with missing data for some, but not all, the follow-up 
visits were included for the years with available data.
All statistical tests were two-sided and P values ≤0.050 
were considered statistically significant. Descriptive 
summaries were provided for baseline characteristics 
and clinical end points at each year of GH treatment 
and reported as mean (standard deviation (s.d.)) unless 
otherwise noted. Differences in ΔHSDS and ΔIGF-I SDS 
at each year of GH treatment were compared by analysis 
of covariance (ANCOVA), with diagnostic population, 
gender and baseline age as fixed effect covariates. Least-
squares (LS) means for ΔHSDS and ΔIGF-I SDS at year 3 
were estimated using the Tukey–Kramer test. All analyses 
were performed using SAS version 9.3 (SAS Institute).
Results
Demographics and baseline characteristics by SGA, 
IGHD subpopulations
Of the 14,680 GH-naïve children who enrolled in ANSWER 
by the end of July 2016, 882 met all inclusion criteria and 
were included in this analysis. The subpopulations in this 
analysis were SGA and GH sufficient (peak GH ≥10 ng/mL, or 
≥20 mIU/L), SGA with GH deficiency (peak GH <10 ng/mL, 
or <20 mIU/L), IGHD born SGA, IGHD not born SGA and 
ISS. The majority of these patients were diagnosed with 
IGHD and not born SGA (n = 709); the second largest 
subpopulation was those diagnosed with IGHD who were 
also born SGA (n = 86) (Table  1). Mean BA/CA was not 
statistically different among subpopulations, although 
statistical differences in means for all other parameters 
were found. Mean (s.d.) peak GH (ng/mL) levels were 
higher for children born SGA who were GH sufficient 
(17.04 (5.08)) compared to those born SGA who were GH 
deficient. For children with IGHD, those who met criteria 
for SGA had lower mean (s.d.) peak GH (ng/mL) levels 
compared to those with IGHD who did not meet criteria 
for SGA (6.82 (5.30) vs 7.44 (7.11)). Mean (s.d.) birth 
length SDS (BL SDS) was lower for children born SGA who 
were GH sufficient (−2.75 (1.97)) compared to those born 
SGA who were GH deficient (−2.08 (1.35)). Mean (s.d.) 
birth weight SDS (BW SDS) was lower for children born 
SGA who were GH sufficient (−2.50 (0.72)) compared to 
children born SGA with GH deficiency (−1.89 (1.12)).
GH response and treatment summaries by year after 
enrollment and subpopulation
In general, the growth-related outcomes, IGF-I SDS, BMI 
SDS and HSDS improved over the 3  years of follow-up, 
as shown by mean SDS for these outcomes at each 
year after enrollment (Table  2). For all five patient 
groups, BA/CA increased slightly from year 1 to year 3. 
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Among patients born SGA, mean (s.d.) BMI SDS from year 1 
to year 3 increased more for those with GH deficiency 
(−0.85 (2.28) to −0.21 (1.11)) compared with those who 
were GH sufficient (year 1, −0.90 (1.43); year 3, −0.57 
(1.06)). However, differences in mean (s.d.) height SDS 
from year 1 to year 3 were greater for patients born SGA 
who were GH sufficient (year 1, −2.43 (0.71); year 3, 
−1.63 (0.73)) compared to patients born SGA who were 
GH deficient (year 1, −1.89 (0.60); year 3, −1.18 (0.79)). 
Increase in mean (s.d.) IGF-I SDS was also greater for 
patients born SGA with GH deficiency (year 1, −0.11 (1.46); 
year 3, 1.19 (2.29)) compared to patients born SGA who 
were GH sufficient (year 1, 0.68 (2.17); year 3, 1.40 (1.14)). 
Improvements in growth-related outcomes were greater 
for IGHD patients who were not born SGA compared to 
those with IGHD who were born SGA. Increases in mean 
(s.d.) HSDS from year 1 to year 3 were slightly greater for 
patients with IGHD not born SGA (−1.86 (0.78) to −1.04 
(0.80)) than for patients with IGHD born SGA (−2.08 (0.69) 
to −1.34 (0.72)). Similarly, increase in mean (s.d.) BMI SDS 
was greater for IGHD patients not born SGA (year 1, −0.18 
(1.10); year 3, 0.02 (1.07)) compared to IGHD patients 
born SGA (year 1, −0.43 (1.16); year 3, −0.28 (1.03)). Of 
note, mean (s.d.) IGF-I SDS increased from 0.19 (1.69) to 
1.00 (1.54) from year 1 to year 3 for IGHD patients not 
born SGA compared to an increase of 0.96 (1.54) to 1.03 
(1.42) for IGHD patients born SGA.
Change from baseline in GH response and treatment 
by year after enrollment and subpopulation
Consistent with these response data, mean ΔHSDS relative 
to baseline levels progressively increased over each year 
of follow-up for each patient subpopulation (Fig.  1). 
Increases in mean ΔHSDS were similar between SGA 
patients with GH deficiency (0.23 in year 1 to 1.08 in 
year 3) and patients born SGA and GH sufficient (0.31 in 
year 1 to 1.15 in year 3). Patients with IGHD not 
born SGA had a greater increase in mean ΔHSDS (0.35 in 
year 1 to 1.19 in year 3) than patients with IGHD born 
SGA (0.44 in year 1 to 1.22 in year 3). Patients with ISS 
had the lowest mean ΔHSDS of all subgroups at year 3.
Differences by subpopulation in changes in HSDS 
from baseline: repeated measurements mixed 
model results
To control for potential covariates influencing ΔHSDS 
results, differences were also compared by ANCOVA and 
adjusted for year of follow-up, gender, baseline age and 
baseline HSDS, with an estimated difference from baseline 
of 0.5855 (Table  3). Significant differences in ∆HSDS 
between subpopulations remained after adjusting for 
each of these variables. Additional estimates quantified 
differences in ∆HSDS compared with a specific reference 
population (ie, the IGHD not born SGA group, which had 
the greatest ∆HSDS during GH treatment). Compared to 
the IGHD not born SGA population, individuals with ISS 
and those born SGA with peak GH ≥10 ng/mL or ≥20 mIU/L 
also showed significant improvements in ∆HSDS with 
GH treatment. Overall, the study population showed a 
significant improvement in ∆HSDS, measured as yearly 
change over baseline, by 0.8070 s.d. in year 3 over year 1. 
A significant decline in ∆HSDS by approximately 0.059 was 
estimated per each year of delay in start of treatment. For 
each unit of increase in baseline HSDS, improvement from 
GH treatment declined by an estimated 0.1275 ΔHSDS.
Table 1 Demographics and baseline characteristics by reported diagnosesa.
SGA, peak GH  
≥10 ng/mL
SGA (non-IGHD), peak GH 
<10 ng/mL
IGHD  
born SGA
IGHD not  
born SGA ISS P value
n 28 15 86 709 44
Male, n (%) 18 (64.3) 6 (40.0) 58 (67.4) 578 (81.5) 37 (84.1) <0.001
Age, mean (s.d.) (years) 7.18 (3.40) 7.71 (2.75) 8.32 (3.30) 9.80 (2.96) 10.41 (2.35) <0.001
Mean (s.d.)
 IGF-I SDS −1.51 (1.34) −1.06 (1.66) −1.22 (1.51) −1.88 (1.55) −0.65 (2.08) <0.001
 BA/CA 0.78 (0.18) 0.79 (0.18) 0.83 (0.19) 0.83 (0.16) 0.85 (0.12) 0.43
 BMI SDS −1.07 (1.51) −0.72 (2.06) −0.41 (1.26) −0.24 (1.28) −0.31 (1.06) 0.008
 Peak GH (ng/mL) 17.04 (5.08) 5.72 (2.84) 6.82 (5.30) 7.44 (7.11) 14.61 (3.95) <0.001
 Height SDS −2.78 (0.71) −2.29 (0.60) −2.56 (0.76) −2.25 (0.78) −2.13 (0.46) <0.001
 BL SDS −2.75 (1.97) −2.08 (1.35) −3.67 (3.25) 0.07 (1.01) −0.35 (0.80) <0.001
 BW SDS −2.50 (0.72) −1.89 (1.12) −2.48 (0.91) −0.37 (1.08) −0.68 (0.69) <0.001
 GH dose (mg/kg/day) 0.05 (0.02) 0.05 (0.02) 0.05 (0.01) 0.05 (0.01) 0.06 (0.02) <0.001
aSubpopulations are mutually exclusive; patients with IGHD born SGA were not included in SGA groups.
BA/CA, bone age/chronological age; BL, birth length; BMI, body mass index; BW, birth weight; GH, growth hormone; IGF-I, insulin-like growth factor 1; IGHD, 
isolated growth hormone deficiency; ISS, idiopathic short stature; s.d., standard deviation; SDS, standard deviation score; SGA, small for gestational age.
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Differences by subpopulation in changes in IGF-I 
SDS from baseline: repeated measurements mixed 
model results
ANCOVA was similarly used to estimate differences in 
ΔIGF-I SDS while adjusting for year of follow-up, gender, 
baseline age and baseline HSDS. After controlling for each 
of these variables, significant differences were observed 
between subpopulations in ∆IGF-I SDS (Table  4). The 
GH-sufficient SGA subpopulation showed the greatest 
improvement from baseline in ΔIGF-I SDS (estimated 
0.269 compared with the reference subpopulation (IGHD 
not born SGA)). In comparison, the GH-deficient SGA 
population had an estimated ΔIGF-I SDS improvement 
of −0.305. In the overall study population, ΔIGF-I SDS 
compared with year 1 improved significantly in year 2 
(estimated 0.5443) and in year 3 (estimated 0.7387).
Mixed models LS means for ∆HSDS and ∆IGF-I SDS 
at year 3 by subpopulation
Estimates of ∆HSDS and ΔIGF-I SDS at year 3 were 
generated as LS means by assigning mean values for all 
other covariates (male, 79%; baseline age, 9.6  years; 
enrollment HSDS, −2.27; enrollment IGF-I SDS, −1.57) 
(Table 5). The estimate for ∆HSDS at year 3 was higher for 
patients born SGA with GH deficiency, with an LS mean 
of 1.0575, compared to patients born SGA who were GH 
sufficient (LS mean, 0.9713). Conversely, the estimate for 
∆IGF-I SDS at year 3 was higher for patients born SGA 
who were GH sufficient (LS mean, 2.8806) compared 
to patients born SGA who were GH deficient (LS mean, 
2.3263). For IGHD patients, those born SGA had a lower 
estimated ∆HSDS at year 3 (LS mean, 1.1693) compared to 
IGHD patients who were not born SGA (LS mean, 1.2142). 
Estimated ∆IGF-I SDS was higher for patients with IGHD 
born SGA (LS mean, 2.7341) compared to IGHD patients 
not born SGA (LS mean, 2.6273).
Discussion
This analysis of data from the ANSWER Program 
demonstrates that treatment with GH resulted in 
improved growth outcomes for children with IGHD 
or SGA (GH sufficient or deficient) and ISS. With few 
exceptions, improvements were shown in all outcomes 
(IGF-I SDS, BMI SDS and HSDS) for all population groups 
over 3 years of treatment. Increases in ∆HSDS over time 
are consistent with results reported in other ANSWER Ta
b
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publications (9, 13, 26). Previous publications have 
evaluated the effects of gender (26), age (9, 26), diagnosis 
(6) and baseline auxological characteristics (BMI, HSDS, 
IGF-I) (13) on responses to GH therapy; however, effects 
of birth size independent of GH status have not previously 
been assessed. In patients born SGA, effect of GH status 
(deficiency or sufficiency) on response to GH therapy is 
also unknown.
Improvements in mean HSDS were observed for 
all patient subpopulations, indicating the benefits of 
GH treatment. In the analysis presented here, two 
subpopulations of patients with GHD who were born SGA 
were compared: those who were primarily diagnosed with 
SGA and found to be GH insufficient and those who were 
diagnosed with IGHD and whose historical auxological 
data fulfilled criteria for SGA. The SGA group who were 
GH insufficient showed a greater improvement in HSDS 
than patients with IGHD born SGA. Previous reports of 
data from the ANSWER Program indicated that increases 
in HSDS were similar between patients born SGA and 
Figure 1
Mean and SDS change from baseline HSDS over 
time.
Table 3 Differences in ΔHSDS from baseline – repeated measurements mixed model results.
Fixed effect Estimate 95% CI LB 95% CI UB T-test P value
Intercept 0.5855 0.4489 0.7221
Subpopulation indicatorsa <0.0001b
 IGHD not born SGA (ref) – – – –
 SGA, peak GH ≥10 ng/mL −0.2419 −0.3842 −0.09961 0.0009
 SGA (non-IGHD), peak GH <10 ng/mL −0.1568 −0.3513 0.03766 0.1139
 IGHD born SGA −0.04442 −0.1301 0.04121 0.3089
 ISS −0.2463 −0.3596 −0.1331 <0.0001
Year indicators <0.0001b
 Year 1 (ref) – – – –
 Year 2 0.4553 0.4312 0.4793 <0.0001
 Year 3 0.8070 0.7829 0.8311 <0.0001
Gender
 Female (ref) – – – –
 Male 0.1062 0.0427 0.1697 0.0011
Age at baseline −0.05898 −0.0677 −0.05026 <0.0001
HSDS at baseline −0.1275 −0.1612 −0.09376 <0.0001
n = 2438 visits by 866 patients.
aAdjusted for year of follow-up, gender, baseline age, and HSDS; boverall F-test P value.
GH, growth hormone; HSDS, height standard deviation score; IGHD, isolated growth hormone deficiency; ISS, idiopathic short stature; LB, lower bound; 
ref, reference; SGA, small for gestational age; UB, upper bound.
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those with IGHD (6, 7). The analyses in those studies, 
however, did not consider GH sufficiency among patients 
born SGA. The data in this report demonstrate the 
variability in responses to GH treatment among patients 
born SGA depending on GH status. For example, increases 
in mean ∆HSDS were greater for patients born SGA who 
were GH sufficient than for patients born SGA who were 
GH insufficient. However, increases in ∆BMI SDS from a 
negative BMI SDS, which is considered a positive response 
to GH therapy and indicates that the patient’s BMI is 
approaching the normal range, were greater for patients 
born SGA who were GH insufficient than for those who 
were GH sufficient. In the IGHD group, GH responses 
also appeared to be affected by SGA status, as patients 
with IGHD not born SGA showed a greater increase in 
mean ∆HSDS than patients with IGHD born SGA. Given 
the variability in response to GH therapy among SGA 
patients, GH status should be considered when setting 
treatment goals. Regarding the ISS cohort, while mean 
daily GH dose was higher for this patient group (0.06 mg/
kg/day vs 0.05 mg/kg/day for all other groups), these 
patients appeared to benefit the least from GH therapy 
(eg, change in HSDS and IGF-I from year 1 to year 3 was 
the least for the ISS cohort). It is important to note that of 
the cohorts analyzed in this study, patients with ISS may 
be the most heterogeneous, as their causes of short stature 
may be variable. Etiologies may include GH resistance/
diminished responsiveness so that larger dosages 
are necessary for clinical responsiveness. Given this 
likelihood, it is recognized that growth responses based 
upon similar dosages cannot be compared meaningfully.
In addition to HSDS, mean IGF-I SDS also increased 
in most patient groups while GH dose remained constant 
over the 3-year period in all groups. Although the IGHD 
born SGA subpopulation demonstrated similar changes in 
HSDS to the other groups, mean IGF-I SDS only increased 
Table 4 Differences in ΔIGF-I SDS from baseline – repeated measurements mixed model results.
Fixed effect Estimate 95% CI LB 95% CI UB T-test P value
Intercept 0.7326 0.3607 1.1044
Subpopulation indicatorsa 0.0208b
 IGHD not born SGA (ref) – – – –
 SGA, peak GH ≥10 ng/mL 0.269 −0.2715 0.8095 0.3289
 SGA (non-IGHD), peak GH <10 ng/mL −0.305 −1.1046 0.4946 0.4542
 IGHD born SGA 0.103 −0.2124 0.4185 0.5215
 ISS −0.6673 −1.0982 −0.2365 0.0024
Year indicators <0.0001b
 Year 1 (ref) – – – –
 Year 2 0.5443 0.4027 0.6858 <0.0001
 Year 3 0.7387 0.5951 0.8823 <0.0001
Gender
 Female (ref) – – – –
 Male 0.3211 0.08136 0.5609 0.0087
Age at baseline −0.01875 −0.05362 0.01613 0.2916
IGF-I SDS at baseline −0.6524 −0.7139 −0.591 <0.0001
n = 1495 visits by 712 patients.
aAdjusted for year of follow-up, gender, baseline age, and HSDS; boverall F-test P value.
GH, growth hormone; IGF-I, insulin-like growth factor 1; IGHD, isolated growth hormone deficiency; ISS, idiopathic short stature; LB, lower bound; ref, 
reference; SDS, standard deviation score; SGA, small for gestational age; UB, upper bound.
Table 5 Mixed models least-squares means for ∆HSDS and ∆IGF-I SDS at year 3.
Pairwise comparison
∆HSDS ∆IGF-I SDS
LS meana 95% CI LB 95% CI UB LS meana 95% CI LB 95% CI UB
SGA, peak GH ≥10 ng/mL 0.9713 0.8316 1.1109 2.8806 2.3452 3.4161
SGA (non-IGHD), peak GH <10 ng/mL 1.0575 0.8649 1.2501 2.3263 1.5323 3.1202
IGHD born SGA 1.1693 1.0878 1.2508 2.7341 2.43 3.0382
IGHD not born SGA 1.2142 1.1841 1.2444 2.6273 2.5004 2.7543
ISS 0.9676 0.857 1.0781 1.9685 1.5451 2.392
Mixed model results in Tables 3 and 4.
aAssigned mean values for all other covariates: male = 79%, enrollment age = 9.6 years, enrollment HSDS = −2.27, enrollment IGF-I SDS = −1.57.
GH, growth hormone; HSDS, height standard deviation score; IGF-1, insulin-like growth factor 1; IGHD, isolated growth hormone deficiency; ISS, 
idiopathic short stature; LB, lower bound; LS, least squares; SGA, small for gestational age; UB, upper bound.
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from 0.96 to 1.03. In comparison, the other groups with 
GH insufficiency demonstrated greater increases in IGF-I 
SDS; the IGHD not born SGA group increased from 0.19 
in year 1 to 1.00 in year 3, and SGA with GH deficiency 
group increased from −0.11 to 1.19; the SGA and GH 
sufficient group also showed a greater increase in IGF-I 
SDS, from 0.68 in year 1 to 1.40 in year 3.
The repeated measurements model for ∆HSDS derived 
from this analysis indicates that older baseline age and 
having a lower difference in HSDS at baseline may 
reduce the effect of GH treatment on HSDS. The model 
is consistent with findings from other analyses on data 
from the ANSWER Program that included patients with 
GHD, SGA and ISS, which demonstrated that younger 
age at baseline and lower baseline HSDS were factors that 
were associated with higher ∆HSDS after approximately 
4  years of GH treatment (7, 13). This result reiterates 
the importance of initiating GH therapy at a young age, 
which has been emphasized before.
There are several potential limitations of this study. 
Given that the ANSWER Program is an observational 
study, there may be variations in data collection due to 
the large number of investigators who participated. In 
addition, it was at the discretion of the reporting physician 
to provide their patient’s diagnosis, and thus, variability 
among physicians’ diagnoses contribute to a certain lack 
of uniformity. There is also potential for information bias 
due to missing or erroneous data points resulting from 
misdiagnosis or failure to report confounding variables. 
Differences in laboratory assays (eg, IGF-I assays, GH 
assays) and diagnostic procedures among sites reporting 
information may affect outcomes, and considering 
the variability in IGF-I assays, this especially limits 
interpretation of IGF-I data. Another potential limitation 
is the differences in availability of diagnostic technologies 
among clinics; for this reason, some patients may be 
missing results for some tests, such as the GH stimulation 
test. Further, as noted earlier, there are situations of GH 
resistance that may occur within the categorical diagnoses 
of both ISS and SGA that are difficult to diagnose or that 
are yet to be described.
In conclusion, results of this analysis demonstrate 
that the greatest benefits of GH treatment were shown for 
patients diagnosed with IGHD who were not born SGA, 
those diagnosed with IGHD who were born SGA and 
those born SGA who were GH deficient. Of note, among 
patients with IGHD, birth size appears to affect response 
to GH therapy, as IGHD patients who were not born SGA 
showed greater improvements in growth-related outcomes 
compared to IGHD patients who were born SGA. Regarding 
patients born SGA, GH responses were variable between 
those who were GH sufficient and those who were GH 
deficient. While the assessment of GH status in patients 
born SGA has not been recommended in the literature or 
by existing guidelines, the results reported here suggest 
that determining GH status may help explain some of the 
variation in response to GH therapy in children born SGA. 
Therefore, GH status may be yet another consideration 
for GH therapy optimization in these patients. Further 
studies, including genetic analyses, are needed to elucidate 
additional aspects of SGA that impact growth.
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